Tuesday, August 4, 2026

Policy

Policy•Fierce Biotech•Aug 3, 2026

After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company

background ▾

• •Guido Oelkers (Sobi CEO) confirmed as BioNTech's next CEO, with an effective date of February 1, 2027 at the latest, ending a contentious six-month vacancy after founders Şahin and Türeci departed to launch a competing mRNA venture.
• •Oelkers assumes leadership during BioNTech's most catalytic pipeline phase, with 2026 expected to deliver Phase 3 readouts for trastuzumab pamirtecan, gotistobart, and pumitamig as the company executes its strategy to become a 'fully integrated immunotherapy powerhouse.'
• •The appointment signals a strategic shift from founder-led innovation to disciplined operational execution; monitor whether Oelkers' specialty pharma playbook (M&A, focused launches) and capital discipline will stabilize BioNTech's valuation and pipeline or create cultural friction with its mRNA science foundation.

BioNTechSobiPfizerComirnatytrastuzumab pamirtecangotistobart

→ Read original article

Policy•Fierce Biotech•Aug 3, 2026

Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea

background ▾

• •AstraZeneca and BMS held merger discussions that would create a ~$400 billion company—potentially the largest pharma megamerger ever—but early reports suggest only exploratory talks with no certainty of deal completion.
• •Significant therapeutic portfolio overlaps in anti-CTLA-4 inhibitors (Yervoy vs. Imjudo), anti-PD-(L)1 agents (Opdivo vs. Imfinzi), CAR-T therapies (Abecma vs. AZD0120), and ADCs (Datroway vs. izalontamab brengitecan) would create substantial antitrust hurdles and force divestitures or program terminations.
• •Watch for: regulatory and antitrust authority statements from FTC/DOJ and UK/EU competition bodies; any formal announcement or denial from AZ and BMS; and whether preliminary talks advance to substantive negotiations given the editorial consensus that strategic rationale is weak.

AstraZenecaBristol Myers SquibbTakedaYervoyImjudoOpdivo

→ Read original article

Policy•STAT News•Aug 4, 2026

Opinion: How Josée became one of the 7.9% of Québécois who die by assisted suicide

background ▾

→ Read original article

Policy•STAT News•Aug 4, 2026

Opinion: I’m using not-FDA-approved software to manage my diabetes. I’ve never felt better

background ▾

• •FDA's statutory authority under 50-year-old device legislation is fundamentally misaligned with software development velocity, creating an incentive for patients to adopt unregulated alternatives that may work better but lack safety oversight
• •The FDA's existing software pre-certification pilot program cannot be fully implemented without Congressional statutory reform, which presents a concrete opportunity during the 2025 FDA user fee reauthorization negotiations
• •Watch the January 2025 FDA user fee reauthorization debate in Congress for proposed statutory changes to enable adaptive regulation of medical software and generative AI applications

→ Read original article

Policy•KFF•Aug 3, 2026

How Much and Why ACA Marketplace Premiums Are Going Up in 2027

background ▾

• •Median ACA Marketplace premium increase of 15% proposed for 2027—second-highest requested rate change since 2018

→ Read original article

Market Access

Market Access•Fierce Biotech•Aug 3, 2026

Curium strikes up to $8B deal for radiopharma rival Lantheus

background ▾

• •Curium-Lantheus merger creates an integrated nuclear medicine leader controlling the full supply chain from isotope production through diagnostic imaging and targeted radionuclide therapy, addressing sector consolidation trends and manufacturing bottlenecks.
• •Lantheus' recent pipeline setbacks—FDA rejection of LNTH-2501 manufacturing application in June and Eli Lilly collaboration abandonment on PSMA therapeutic due to unfavorable phase 3 OS data—may have influenced the acquisition timing and valuation.
• •CVR structure ($12/share tied to 2030 sales milestones for Pylarify, Definity, and Neuraceq franchises) signals confidence in these core products but reflects execution risk; monitor Lantheus Q2 earnings (Aug 6) and regulatory path for pending candidates like Octevy post-acquisition.

CuriumLantheus Medical TechnologiesCapVest PartnersPylarifyDefinityNeuraceq

→ Read original article

Market Access•Fierce Biotech•Aug 3, 2026

‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree

background ▾

• •Madrigal has deployed $255M+ in acquisitions since Rezdiffra's 2024 approval to build a diversified MASH combination therapy pipeline across distinct mechanisms (DGAT2i, siRNA, RNAi, GLP-1), signaling confidence in blockbuster potential and first-mover advantage
• •CEO Sibold's explicit strategy to acquire "anything that makes sense mechanistically" reflects conviction that MASH—historically the "graveyard of drug development" with 23 prior failures—is now a solvable market, with clear commercial upside from combination therapy positioning
• •Watch for Phase 2/3 readouts on combination regimens with Rezdiffra and competitive responses from Eli Lilly, Novo Nordisk, and other large pharma programs; reimbursement strategy for multi-drug regimens will be critical to validate portfolio ROI

Madrigal PharmaceuticalsPfizerRibo Life ScienceRezdiffraDGAT2isiRNA

→ Read original article

Market Access•Endpoints News•Aug 4, 2026

Pathos does deals with AstraZeneca, China's Alphamab, seeks up to $300M Series E

background ▾

• •Pathos secured dual partnerships with a major pharma (AstraZeneca) and a leading Chinese biotech (Alphamab), validating its ADC platform technology
• •Series E financing goal of $300M signals significant capital raise and investor confidence in the company's technology and partnerships
• •Specific program details, milestone payments, and long-term development roadmaps are not disclosed

Pathos TherapeuticsAstraZenecaAlphamab

→ Read original article

Market Access•Fierce Biotech•Aug 3, 2026

BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger

background ▾

• •BlossomHill's lead asset BH-30643 is differentiated by targeting C797S-mediated resistance to third-generation EGFR TKIs, positioning it against an estimated $7+ billion market dominated by AstraZeneca's Tagrisso, though the resistance-associated indication represents a narrower patient population than front-line use.
• •The $70 million allocation to BH-30643 signals the company's intent to pursue registrational phase 2 data; clinical trial outcomes will be critical to validating the resistance-mutation strategy and supporting future partnering or advancement decisions.
• •Watch for phase 1/2 efficacy and safety data on BH-30643, competitive readouts from other EGFR inhibitor programs targeting resistant mutations, and whether the C797S-resistance indication gains payer traction given likely orphan-like patient numbers.

BlossomHill TherapeuticsAstraZenecaJohnson & JohnsonBH-30643TagrissoRybrevant

→ Read original article

Market Access•Endpoints News•Aug 3, 2026

Update: Supernus, Indivior to merge and form CNS-focused drugmaker

background ▾

• •All-stock merger combining two established CNS players (Supernus and Indivior) to create a stronger market competitor
• •Combined entity positioned as a leader in CNS therapeutics, suggesting complementary pipelines and commercial strengths
• •Merger timing, closing conditions, governance structure, and pipeline priorities require clarification

Supernus PharmaceuticalsIndivior

→ Read original article

Clinical Trials

No articles for this category on this date.